According to these results, Van Veen et al. have shown that the CTLA-4-318, CTLA-4 + 49, and CD28-I3 + 17 polymorphisms were not associated with the risk of developing MS and did not change the course of the disease [141]. Here, CD28 is linked to myeloid sarcoma.